You owe the elasticity and firmness of your skin to the all-purpose seamless protein
Lean mass loss was reported for patients on semaglutide (~10% loss relative to baseline) and tirzepatide (~11% loss relative to baseline) during Phase III clinical trials, STEP-1, NCT03548935 and SURMOUNT-1, NCT04184622, respectively 61, 62
- Melasma - Post-inflammatory hyperpigmentation - Uneven skin tone - Dullness Together, they provide a gentle but effective solution for stubborn discoloration and lackluster skin
BPC-157 is not an FDA-approved drug, which means it is not available as a retail prescription product
Khavinson VKh, Izmaylov DM, Obukhova LK, Malinin VV
This color is expected and confirms the integrity of the copper complex